Epogen, Procrit, Epoetin Alfa Newswire

Epogen, Procrit, Epoetin Alfa Newswire

Comprehensive Real-Time News Feed for Epogen, Procrit, Epoetin Alfa (generic).

Results 1 - 20 of 250 in Epogen, Procrit, Epoetin Alfa (generic)

  1. Chemotherapy Induced Anemia Market to Register Substantial Expansion by 2026Read the original story w/Photo

    Sunday Nov 5 | PR-inside.com

    Anemia is a most common hematologic disorder in majority of cancer patients receiving chemotherapy treatment. Anemia is a condition in which person do not have sufficient red blood cells in the body or low ability of hemoglobin to carry oxygen and circulate it to all cells in the body.

    Comment?

  2. Erythropoietin Drugs Market Insights Trends Outlook and Analysis, 2016-2024Read the original story w/Photo

    Thursday Nov 2 | PR-inside.com

    The erythropoietin alfa biosimilars have gained significant traction in the past two years and the market will witness the introduction of new biosimilars as the existing erythropoietin drugs undergo patent expiration. Erythropoietin alfa is widely used to treat anemia and increase the red blood cells count in the body.

    Comment?

  3. Amgen to pay Kirin $780M for ownership of joint ventureRead the original story w/Photo

    Tuesday Oct 31 | Seeking Alpha

    Amgen and Kirin Holdings, equal partners in a joint venture to develop a range of products from EPOGEN to brodalumab that began in 1984, have agreed to Amgen taking sole ownership of the venture. Under the terms of the agreement, Amgen will pay Kirin $780M and up to an additional $30M upon the achievement of certain sales targets.

    Comment?

  4. Kirin Cashes Out of Amgen Drug Joint Venture for $780MRead the original story w/Photo

    Monday Oct 30 | BioSpace

    Amgen today announced that Amgen and Kirin Holdings have agreed that Kirin-Amgen , a joint venture between the two companies, will redeem Kirin's shares in the joint venture and, as a result, Kirin-Amgen will become a wholly-owned subsidiary of Amgen. Kirin-Amgen was established in 1984 as a 50-50 joint venture between Amgen and Kirin to fund the global development of EPOGENA .

    Comment?

  5. Contrasting AmgenRead the original story w/Photo

    Thursday Oct 26 | IntersportsWire

    Amgen and Tetraphase Pharmaceuticals are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability. Amgen has higher revenue and earnings than Tetraphase Pharmaceuticals.

    Comment?

  6. Amgen Inc. (AMGN) Issues Quarterly Earnings ResultsRead the original story w/Photo

    Wednesday Oct 25 | AmericanBankingNews.com

    Amgen Inc. released its quarterly earnings data on Wednesday. The medical research company reported $3.27 earnings per share for the quarter, beating the consensus estimate of $3.11 by $0.16, Bloomberg Earnings reports.

    Comment?

  7. Contrasting Amgen (AMGN) and The CompetitionRead the original story w/Photo

    Monday Oct 23 | IntersportsWire

    Amgen is one of 116 publicly-traded companies in the "Pharmaceuticals" industry, but how does it compare to its competitors? We will compare Amgen to related companies based on the strength of its risk, profitability, valuation, analyst recommendations, dividends, institutional ownership and earnings. 78.1% of Amgen shares are held by institutional investors.

    Comment?

  8. Head to Head Contrast: Tetraphase PharmaceuticalsRead the original story w/Photo

    Monday Oct 23 | AmericanBankingNews.com

    Tetraphase Pharmaceuticals and Amgen are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability. 41.7% of Tetraphase Pharmaceuticals shares are held by institutional investors.

    Comment?

  9. Amgen Inc. (AMGN) Set to Announce Earnings on WednesdayRead the original story w/Photo

    Monday Oct 23 | Daily Political

    Amgen Inc. will release its earnings data after the market closes on Wednesday, October 25th. Analysts expect Amgen to post earnings of $3.11 per share for the quarter.

    Comment?

  10. Reviewing Amgen (AMGN) and The CompetitionRead the original story w/Photo

    Saturday Oct 21 | Daily Political

    Amgen is one of 116 public companies in the "Pharmaceuticals" industry, but how does it weigh in compared to its competitors? We will compare Amgen to related companies based on the strength of its analyst recommendations, valuation, earnings, profitability, institutional ownership, dividends and risk. Amgen pays an annual dividend of $4.60 per share and has a dividend yield of 2.5%.

    Comment?

  11. Amgen Inc. (AMGN) Earns "Hold" Rating from BMO Capital MarketsRead the original story w/Photo

    Friday Oct 20 | AmericanBankingNews.com

    's stock had its "hold" rating reaffirmed by research analysts at BMO Capital Markets in a research note issued to investors on Friday. They presently have a $198.00 target price on the medical research company's stock.

    Comment?

  12. Canada Pension Plan Investment Board Boosts Stake in Amgen Inc.Read the original story w/Photo

    Friday Oct 20 | Daily Political

    Canada Pension Plan Investment Board grew its holdings in Amgen Inc. by 65.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,706,261 shares of the medical research company's stock after acquiring an additional 676,300 shares during the quarter.

    Comment?

  13. Kelly Lawrence W & Associates Inc. CA Has $900,000 Holdings in Amgen Inc.Read the original story w/Photo

    Thursday Oct 19 | IntersportsWire

    Kelly Lawrence W & Associates Inc. CA continued to hold its position in shares of Amgen Inc. during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,223 shares of the medical research company's stock at the close of the 2nd quarter.

    Comment?

  14. Head to Head Review: AmgenRead the original story w/Photo

    Oct 18, 2017 | Daily Political

    Amgen and Opko Health are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability. Amgen has higher revenue and earnings than Opko Health.

    Comment?

  15. FibroGen Announces Acceptance by China FDA of Roxadustat New Drug...Read the original story

    Oct 18, 2017 | Customer Interaction Solutions

    FibroGen, Inc. , a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd. , today announced that the China Food and Drug Administration has accepted the company's recently submitted New Drug Application for registration of roxadustat , a novel oral investigational treatment for anemia in dialysis-dependent CKD and non-dialysis-dependent CKD patients. Under the terms of FibroGen's agreement with AstraZeneca, the NDA submission triggers a $15 million milestone payment, payable to FibroGen by AstraZeneca.

    Comment?

  16. Barclays PLC Boosts Amgen Inc. (AMGN) Price Target to $190.00Read the original story w/Photo

    Oct 17, 2017 | Daily Political

    The brokerage currently has an equal weight rating on the medical research company's stock. Other analysts also recently issued reports about the stock.

    Comment?

  17. Analyzing Amgen (AMGN) and The CompetitionRead the original story w/Photo

    Oct 16, 2017 | AmericanBankingNews.com

    Amgen is one of 115 public companies in the "Pharmaceuticals" industry, but how does it contrast to its competitors? We will compare Amgen to similar companies based on the strength of its earnings, valuation, profitability, risk, dividends, institutional ownership and analyst recommendations. Amgen pays an annual dividend of $4.60 per share and has a dividend yield of 2.5%.

    Comment?

  18. Head to Head Review: AmgenRead the original story w/Photo

    Oct 15, 2017 | AmericanBankingNews.com

    Amgen and Opko Health are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership. Amgen has higher revenue and earnings than Opko Health.

    Comment?

  19. First National Bank & Trust Co. of Newtown Has $517,000 Holdings in Amgen Inc.Read the original story w/Photo

    Oct 14, 2017 | IntersportsWire

    First National Bank & Trust Co. of Newtown continued to hold its stake in Amgen Inc. during the second quarter, according to the company in its most recent disclosure with the SEC.

    Comment?

  20. Barclays PLC Increases Amgen Inc. (AMGN) Price Target to $190.00Read the original story w/Photo

    Oct 13, 2017 | AmericanBankingNews.com

    The firm currently has an "equal weight" rating on the medical research company's stock. Barclays PLC's price target would indicate a potential upside of 3.82% from the stock's previous close.

    Comment?